InBrain Pharma is a clinical-stage biopharmaceutical company that develops personalized therapies for neurodegenerative diseases, focusing on dopamine titration for advanced Parkinson’s disease. Its lead therapeutic approach titrates dopamine in the brain via circadian intracerebroventricular infusion and is being developed under the PERCEPAR project. The company holds a global license from SATT Nord to exploit patents covering this therapeutic approach. InBrain intends to use the €1.8M it recently raised to support the PERCEPAR program. The underlying innovation stems from research by Professors David Devos and Caroline Moreau at the University of Lille, Lille Neuroscience & Cognition UMR-S 1172 INSERM, and Lille University Hospital. Founded in 2018 and based in Lille, France, the company positions itself in personalized neurology for advanced-stage Parkinson’s patients.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

May 2025